Status:
NOT_YET_RECRUITING
Antimicrobial Therapeutic Drug Monitoring During Lung Transplant Perioperative Phase
Lead Sponsor:
Policlinico Hospital
Conditions:
Lung Transplant Infection
Pneumonia, Bacterial
Eligibility:
All Genders
18+ years
Brief Summary
Background: Post-LUTX pneumonia represents a leading cause of death along the first month after LUTX. Donor-derived transmission of pathogenic species occurs up to 25% of recipients receiving a graft ...
Detailed Description
1. BACKGROUND Lung Transplantation (LUTX) is the curative treatment for selected patients with end-stage lung disease. Despite continuous optimization of recipients perioperative phase morbidity a...
Eligibility Criteria
Inclusion
- Recipient of LUTX
- Age \> 18 years
- Signed informed consent
Exclusion
- Age \< 18 years old
- Already undergone LUTX
- Documented respiratory colonization in the 12 months preceding LUTX
- Undergoing any antimicrobial therapy preceding LUTX
- Documented post-LUTX endobronchial plasma leak requiring high levels of PEEP \> 15 cmH2O.
Key Trial Info
Start Date :
July 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06583642
Start Date
July 1 2025
End Date
March 1 2027
Last Update
May 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Ca'Granda - Ospedale Maggiore Policlinico
Milan, Milan, Italy, 20122